Guide

Sponsor responsibilities for clinical investigators

A trial sponsor’s responsibilities toward its clinical investigators are set out in 21 CFR part 312, subpart D: select clinical investigators who are qualified, give them what they need to conduct the study properly, monitor the investigation, and act when an investigator does not comply. The sponsor remains ultimately responsible for the quality and integrity of the trial data whatever the investigator does — which is why what FDA tells a sponsor, and what it does not, matters.

The duties, by regulation

General responsibilities — 21 CFR 312.50. Selecting qualified clinical investigators, providing them the information they need to conduct the investigation properly, ensuring proper monitoring, ensuring the investigation is conducted in accordance with the general investigational plan and protocols in the IND, maintaining an effective IND, and ensuring FDA and all participating investigators are promptly informed of significant new adverse effects or risks.

Example 483 finding: “Failure to ensure proper monitoring of the study and ensure the study is conducted in accordance with the protocol and/or investigational plan.”

Selecting investigators and monitors — 21 CFR 312.53. Select only clinical investigators qualified by training and experience; ship investigational drug only to participating investigators; obtain before the study a signed Form FDA 1572, a CV or statement of qualifications, an outline of the study protocol and financial-disclosure information; select qualified monitors. Detail: clinical investigator selection.

Example 483 finding: “Investigators who were not qualified by training and experience as appropriate experts were selected to investigate a drug.”

Informing investigators — 21 CFR 312.55. Give each participating clinical investigator an investigator brochure and keep them informed of new observations, especially adverse effects and safe use.

Example 483 finding: “Failure to provide to an investigator, prior to the start of an investigation, a brochure containing all of the information required by 21 CFR 312.23(a)(5).”

Review of ongoing investigations — 21 CFR 312.56. Monitor the progress of all investigations. A sponsor who discovers that a clinical investigator is not complying with the signed agreement, the investigational plan or the regulations must promptly either secure compliance or discontinue shipments of the drug and end the investigator’s participation — and, if participation is ended, require the return or disposition of the drug and notify FDA.

Example 483 finding: “Failure to monitor the progress of an investigation conducted under your IND.”

Records, reports and inspection — 21 CFR 312.57–312.58. Maintain records of drug shipment and disposition and of financial interests, and permit FDA to inspect them.

Example 483 finding: “Failure to permit FDA to have access to, review, and copy records or reports related to a clinical investigation.”

ICH E6 restates the same responsibilities in GCP terms, adding that the sponsor is responsible for implementing quality management across the trial and that responsibilities transferred to a CRO remain the sponsor’s to oversee.

What FDA tells a sponsor — and what it does not

The duties above assume the sponsor knows what is happening at its sites. Three facts about how FDA communicates make that assumption the sponsor’s job to satisfy:

FDA sends inspection findings to the clinical investigator, not typically to the sponsor. The Form FDA 483, the classification and any warning letter go to the person inspected. FDA does not typically copy clinical trial sponsors on the results of a clinical investigator inspection.

The clinical investigator is not required to tell the sponsor. Not unless a quality agreement between them says so — and then possibly only for that sponsor’s trial. Large sites often run several trials concurrently, so an inspection may concern another sponsor’s study entirely.

FDA notifies sponsors at disqualification. When a clinical investigator is disqualified under 21 CFR 312.70, FDA notifies the sponsor of any investigation in which the investigator was named. That is the end of a process that began with a NIDPOE letter and, often, a NOOH letter — typically years earlier.

None of this means sponsors are kept in the dark improperly; the inspection is of the clinical investigator, and the findings are the investigator’s to answer. It means that an investigator’s inspection history reaches the sponsor when the sponsor goes and looks, and that “nobody mentioned it” is a real possibility rather than an accusation.

Why the history matters to the sponsor

Because the sponsor is answerable for the data. If a clinical investigator’s conduct casts doubt on a site’s data, FDA may decline to rely on some or all of it in the marketing application. Findings at a site can also lead to scrutiny of the sponsor’s own monitoring and oversight at the sponsor’s inspection: the question “what did you know, and when?” is answered by the selection file. A sponsor that selected an investigator with an OAI in their history and no record of having considered it is in a weaker position than one that considered it, asked for the site’s responses and corrective action plans, and documented a decision.

Meeting the duties in practice

At selection. Check the FDA record — inspections and classifications, findings, warning letters, disqualification proceedings, debarment — alongside credentials and the site qualification visit. Record the check and its date. This is clinical investigator vetting.

During the trial. Monitor as planned, and re-screen the roster periodically against the disqualification and debarment lists and the inspection record; classifications are assigned late, and a site can be inspected mid-study.

When something surfaces. 21 CFR 312.56 gives the choice: secure compliance, or end the clinical investigator’s participation and notify FDA. The site’s responses and corrective action plans are the first thing to ask for.

Questions this page answers

What are a sponsor's responsibilities toward clinical investigators under FDA regulations?

Under 21 CFR 312.50 through 312.58 a sponsor must select clinical investigators qualified by training and experience, obtain a signed Form FDA 1572 and qualifications before the study, inform them about the drug and new risks, monitor the investigation, act on an investigator’s non-compliance, and keep records available for FDA inspection.

Does FDA notify a sponsor when it inspects one of the sponsor's clinical investigators?

Not typically. FDA sends inspection findings to the clinical investigator, not to the sponsor. FDA does notify the sponsor when an investigator is disqualified, which is the end of a lengthy process.

Is a clinical investigator required to tell the sponsor about an FDA inspection?

Not by regulation. The clinical investigator is required to report it only if a quality agreement with the sponsor says so, and then possibly only for that sponsor’s trial.

What must a sponsor do if a clinical investigator is not complying?

Under 21 CFR 312.56, promptly either secure compliance or discontinue shipments of the investigational drug and end the clinical investigator’s participation. If participation is ended, the sponsor must require the return or disposition of the drug and notify FDA.

Can a sponsor transfer these responsibilities to a CRO?

Obligations can be transferred to a CRO in writing (21 CFR 312.52), and the CRO then assumes them. Under the same section, any obligation not covered by the written description is deemed not to have been transferred, so it stays with the sponsor. Separately, ICH E6 keeps the sponsor ultimately responsible for the quality and integrity of the trial data, and for overseeing the CRO.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.